Key facts
- Kovina Therapeutics’s last known valuation is $12.0M.
- It has raised $2.3M across 1 recorded rounds; the latest was Seed Round ($2.0M) in Jun 2021.
- Notable investors include National Institutes of Health, Elevate Ventures, BrightEdge, BioCrossroads, IU Ventures — 9 tracked in total.
- Kovina Therapeutics has filed 1 Form D with the SEC, most recently Jul 2021 ($2.0M sold to 11 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Kovina Therapeutics
Funding rounds
1 roundsAbout Kovina Therapeutics
Operator of a biotechnology company intended to discover a non-surgical, medical treatment for human papillomavirus infections and cancers. The company develops antiviral therapeutics to treat cancers and pre-malignant infections by using drug-like compounds to target and inactivate a key HPV protein always expressed in early, pre-malignant, and cancerous pathologies, enabling medical practitioners to treat patients infected with HPV and cancer.
- Sector
- Healthcare
- HQ
- Indianapolis, IN, United States
- Founded
- 2020
- Employees
- 5
- Website
- kovina.com/
- Ownership
- Privately Held (backing)
Kovina Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kovina Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kovina Therapeutics in its N-PORT filings yet. We sweep new filings monthly.